379 related articles for article (PubMed ID: 36077433)
1. Novel Nanotechnology Approaches to Overcome Drug Resistance in the Treatment of Hepatocellular Carcinoma: Glypican 3 as a Useful Target for Innovative Therapies.
Mossenta M; Busato D; Dal Bo M; Macor P; Toffoli G
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077433
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of antiglypican-3 therapy as a promising target for amelioration of hepatic tissue damage in hepatocellular carcinoma.
Zaghloul RA; El-Shishtawy MM; El Galil KH; Ebrahim MA; Metwaly AA; Al-Gayyar MM
Eur J Pharmacol; 2015 Jan; 746():353-62. PubMed ID: 25449037
[TBL] [Abstract][Full Text] [Related]
3. Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment.
Zhou F; Shang W; Yu X; Tian J
Med Res Rev; 2018 Mar; 38(2):741-767. PubMed ID: 28621802
[TBL] [Abstract][Full Text] [Related]
4. Cellular changes resulting from forced expression of glypican-3 in hepatocellular carcinoma cells.
Kwack MH; Choi BY; Sung YK
Mol Cells; 2006 Apr; 21(2):224-8. PubMed ID: 16682817
[TBL] [Abstract][Full Text] [Related]
5. Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma.
Filmus J; Capurro M
FEBS J; 2013 May; 280(10):2471-6. PubMed ID: 23305321
[TBL] [Abstract][Full Text] [Related]
6. Development and
Ma XH; Wang S; Liu SY; Chen K; Wu ZY; Li DF; Mi YT; Hu LB; Chen ZW; Zhao XM
World J Gastroenterol; 2019 Jun; 25(24):3030-3043. PubMed ID: 31293339
[TBL] [Abstract][Full Text] [Related]
7. Current methods for the detection of glypican-3.
Xiao X; Huang Q; Lin X; Zahid KR; Huang X; Liu T; Zeng T
Anal Methods; 2024 Jan; 16(2):152-160. PubMed ID: 38108085
[TBL] [Abstract][Full Text] [Related]
8. Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions.
Wang HL; Anatelli F; Zhai QJ; Adley B; Chuang ST; Yang XJ
Arch Pathol Lab Med; 2008 Nov; 132(11):1723-8. PubMed ID: 18976006
[TBL] [Abstract][Full Text] [Related]
9. Glypican-3 targeting of liver cancer cells using multifunctional nanoparticles.
Park JO; Stephen Z; Sun C; Veiseh O; Kievit FM; Fang C; Leung M; Mok H; Zhang M
Mol Imaging; 2011 Feb; 10(1):69-77. PubMed ID: 21303616
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of glypican-3 expression via RNA interference influences the growth and invasive ability of the MHCC97-H human hepatocellular carcinoma cell line.
Ruan J; Liu F; Chen X; Zhao P; Su N; Xie G; Chen J; Zheng D; Luo R
Int J Mol Med; 2011 Oct; 28(4):497-503. PubMed ID: 21617840
[TBL] [Abstract][Full Text] [Related]
11. Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma.
Haruyama Y; Kataoka H
World J Gastroenterol; 2016 Jan; 22(1):275-83. PubMed ID: 26755876
[TBL] [Abstract][Full Text] [Related]
12. A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma.
Wu Q; Pi L; Le Trinh T; Zuo C; Xia M; Jiao Y; Hou Z; Jo S; Puszyk W; Pham K; Nelson DR; Robertson K; Ostrov D; Rameshwar P; Xia CQ; Liu C
Mol Ther; 2017 Oct; 25(10):2299-2308. PubMed ID: 28865999
[TBL] [Abstract][Full Text] [Related]
13. Role of Glypican-3 in the growth, migration and invasion of primary hepatocytes isolated from patients with hepatocellular carcinoma.
Montalbano M; Rastellini C; McGuire JT; Prajapati J; Shirafkan A; Vento R; Cicalese L
Cell Oncol (Dordr); 2018 Apr; 41(2):169-184. PubMed ID: 29204978
[TBL] [Abstract][Full Text] [Related]
14. Selenium nanoparticles overcomes sorafenib resistance in thioacetamide induced hepatocellular carcinoma in rats by modulation of mTOR, NF-κB pathways and LncRNA-AF085935/GPC3 axis.
Al-Noshokaty TM; Mesbah NM; Abo-Elmatty DM; Abulsoud AI; Abdel-Hamed AR
Life Sci; 2022 Aug; 303():120675. PubMed ID: 35640776
[TBL] [Abstract][Full Text] [Related]
15. Novel Glypican-3-Binding Peptide for in Vivo Hepatocellular Carcinoma Fluorescent Imaging.
Zhu D; Qin Y; Wang J; Zhang L; Zou S; Zhu X; Zhu L
Bioconjug Chem; 2016 Mar; 27(3):831-9. PubMed ID: 26850086
[TBL] [Abstract][Full Text] [Related]
16. Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy.
Gao W; Kim H; Feng M; Phung Y; Xavier CP; Rubin JS; Ho M
Hepatology; 2014 Aug; 60(2):576-87. PubMed ID: 24492943
[TBL] [Abstract][Full Text] [Related]
17. Glypican-3 immunocytochemistry in liver fine-needle aspirates : a novel stain to assist in the differentiation of benign and malignant liver lesions.
Kandil D; Leiman G; Allegretta M; Trotman W; Pantanowitz L; Goulart R; Evans M
Cancer; 2007 Oct; 111(5):316-22. PubMed ID: 17763368
[TBL] [Abstract][Full Text] [Related]
18. High-Specific Isolation and Instant Observation of Circulating Tumour Cell from HCC Patients via Glypican-3 Immunomagnetic Fluorescent Nanodevice.
Chu Q; Mu W; Lan C; Liu Y; Gao T; Guan L; Fang Y; Zhang Z; Liu Y; Liu Y; Zhang N
Int J Nanomedicine; 2021; 16():4161-4173. PubMed ID: 34168446
[TBL] [Abstract][Full Text] [Related]
19. Iron-Oxide-Based Nanovector for Tumor Targeted siRNA Delivery in an Orthotopic Hepatocellular Carcinoma Xenograft Mouse Model.
Wang K; Kievit FM; Sham JG; Jeon M; Stephen ZR; Bakthavatsalam A; Park JO; Zhang M
Small; 2016 Jan; 12(4):477-87. PubMed ID: 26641029
[TBL] [Abstract][Full Text] [Related]
20. Glypican-3 binds to Frizzled and plays a direct role in the stimulation of canonical Wnt signaling.
Capurro M; Martin T; Shi W; Filmus J
J Cell Sci; 2014 Apr; 127(Pt 7):1565-75. PubMed ID: 24496449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]